Zhitong Finance App News, Hengrui Pharmaceutical (01276.HK) issued an announcement. Recently, Chengdu Shengdi Pharmaceutical Co., Ltd., a subsidiary of Jiangsu Hengrui Pharmaceutical Co., Ltd. (hereinafter referred to as the “Company”), received a notice from the State Drug Administration (hereinafter referred to as the “State Drug Administration”) to approve the launch of the new class 1 drug, Licancopam fumarate (HRS-5965) capsules independently developed by the company.

Zhitong Finance App News, Hengrui Pharmaceutical (01276.HK) issued an announcement. Recently, Chengdu Shengdi Pharmaceutical Co., Ltd., a subsidiary of Jiangsu Hengrui Pharmaceutical Co., Ltd. (hereinafter referred to as the “Company”), received a notice from the State Drug Administration (hereinafter referred to as the “State Drug Administration”) to approve the launch of the new class 1 drug, Licancopam fumarate (HRS-5965) capsules independently developed by the company.